Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia
Abstract Attention‐deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescri...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.12381 |
| _version_ | 1827319246250573824 |
|---|---|
| author | Kentaro Kawabe Fumie Horiuchi Yu Matsumoto Saori Inoue Maya Okazawa Rie Hosokawa Kiwamu Nakachi Junya Soga Shu‐Ichi Ueno |
| author_facet | Kentaro Kawabe Fumie Horiuchi Yu Matsumoto Saori Inoue Maya Okazawa Rie Hosokawa Kiwamu Nakachi Junya Soga Shu‐Ichi Ueno |
| author_sort | Kentaro Kawabe |
| collection | DOAJ |
| description | Abstract Attention‐deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)‐approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first‐line treatment, with pharmacological treatment added as the second‐line treatment. Although Japanese guidelines, including pharmacological treatments, have been established, the guidelines and utilization of ADHD medications across Asian regions are unclear. Therefore, to appropriately evaluate the strategy of pharmacological treatments for ADHD, we investigated Asian regional guidelines for ADHD medication in children. We also reviewed the guidelines in Malaysia, Singapore, India, and the Republic of Korea and found that these guidelines differ from Western guidelines. |
| first_indexed | 2024-04-25T00:16:21Z |
| format | Article |
| id | doaj.art-27d0d80d7a2b48d6a98bd77feac30e92 |
| institution | Directory Open Access Journal |
| issn | 2574-173X |
| language | English |
| last_indexed | 2024-04-25T00:16:21Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuropsychopharmacology Reports |
| spelling | doaj.art-27d0d80d7a2b48d6a98bd77feac30e922024-03-13T03:12:13ZengWileyNeuropsychopharmacology Reports2574-173X2024-03-01441293310.1002/npr2.12381Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in AsiaKentaro Kawabe0Fumie Horiuchi1Yu Matsumoto2Saori Inoue3Maya Okazawa4Rie Hosokawa5Kiwamu Nakachi6Junya Soga7Shu‐Ichi Ueno8Department of Child Psychiatry Ehime University Graduate School of Medicine Toon City JapanDepartment of Child Psychiatry Ehime University Graduate School of Medicine Toon City JapanDepartment of Neuropsychiatry, Molecules and Function Ehime University Graduate School of Medicine Toon City JapanDepartment of Neuropsychiatry, Molecules and Function Ehime University Graduate School of Medicine Toon City JapanDepartment of Neuropsychiatry, Molecules and Function Ehime University Graduate School of Medicine Toon City JapanDepartment of Neuropsychiatry, Molecules and Function Ehime University Graduate School of Medicine Toon City JapanDepartment of Neuropsychiatry, Molecules and Function Ehime University Graduate School of Medicine Toon City JapanDepartment of Neuropsychiatry, Molecules and Function Ehime University Graduate School of Medicine Toon City JapanDepartment of Neuropsychiatry, Molecules and Function Ehime University Graduate School of Medicine Toon City JapanAbstract Attention‐deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)‐approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first‐line treatment, with pharmacological treatment added as the second‐line treatment. Although Japanese guidelines, including pharmacological treatments, have been established, the guidelines and utilization of ADHD medications across Asian regions are unclear. Therefore, to appropriately evaluate the strategy of pharmacological treatments for ADHD, we investigated Asian regional guidelines for ADHD medication in children. We also reviewed the guidelines in Malaysia, Singapore, India, and the Republic of Korea and found that these guidelines differ from Western guidelines.https://doi.org/10.1002/npr2.12381ADHDguanfacineguidelinelisdexamfetaminemethylphenidates |
| spellingShingle | Kentaro Kawabe Fumie Horiuchi Yu Matsumoto Saori Inoue Maya Okazawa Rie Hosokawa Kiwamu Nakachi Junya Soga Shu‐Ichi Ueno Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia Neuropsychopharmacology Reports ADHD guanfacine guideline lisdexamfetamine methylphenidates |
| title | Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia |
| title_full | Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia |
| title_fullStr | Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia |
| title_full_unstemmed | Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia |
| title_short | Practical clinical guidelines and pharmacological treatment for attention‐deficit hyperactivity disorder in Asia |
| title_sort | practical clinical guidelines and pharmacological treatment for attention deficit hyperactivity disorder in asia |
| topic | ADHD guanfacine guideline lisdexamfetamine methylphenidates |
| url | https://doi.org/10.1002/npr2.12381 |
| work_keys_str_mv | AT kentarokawabe practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia AT fumiehoriuchi practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia AT yumatsumoto practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia AT saoriinoue practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia AT mayaokazawa practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia AT riehosokawa practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia AT kiwamunakachi practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia AT junyasoga practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia AT shuichiueno practicalclinicalguidelinesandpharmacologicaltreatmentforattentiondeficithyperactivitydisorderinasia |